Based on these in vivo CDK14 inhibitor administration experiments, we hypothesize that blockage of CDK14 activity reduces loads of pathology-linked forms of insoluble α-Syn, potentially shifting synucleinopathy progression to an earlier phase of disease development. This evidence concerns the gene CDK14 and synucleinopathy.